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Purpose: The present study was conducted to determine and compare the target 
attainment rate (TAR) between microorganism-nonspecific (Ctrough) and microor-
ganism-specific (AUC24/MIC) targets over two weeks of teicoplanin administra-
tion according to several dose regimens for the treatment of Staphylococcus aureus 
in Korean patients with neutropenic fever. Materials and Methods: One thousand 
virtual concentrations were obtained for each dose using the population pharmaco-
kinetic parameters of teicoplanin adopted from a published study. Simulation of 
1,000 virtual MICs was performed using the MICs of 78 clinical isolates of S. au-
reus collected from a hospital in Korea. Thereafter, these simulated MICs were 
randomly allocated to 1,000 virtual patients in whom the TARs for AUC24/MIC 
>125 [or 345] and Ctrough >10 [or 20] mg/L were determined. The relationship of 
the maintenance dose with the steady-state TAR was predicted with respect to the 
AUC24/MIC >125 [or 345] using logistic analysis. Results: The standard dose reg-
imen of teicoplanin showed TARs of about 70% [or 33%] and 70% [or 20%] at 
steady-state in cases with AUC24/MIC >125 [or 345] and Ctrough >10 [or 20] mg/L, 
respectively. Conclusion: The current standard dose regimen was predicted to be 
insufficient to adequately treat S. aureus in Korean patients with neutropenic fever. 
To assure at least an 80% TAR in this population, dose adjustment of teicoplanin 
should be considered.
Key Words:    Teicoplanin, Staphylococcus aureus, neutropenia, pharmacokinetics, 
pharmacodynamics
INTRODUCTION
Teicoplanin, one of the glycopeptide antibiotics, is primarily active against Gram-
positive microorganisms including Staphylococcus, Streptococcus, and Enterococ-
cus species. During chemotherapy for hematologic malignancies, Gram-positive 
bacterial infections are a common cause of neutropenic fever in Korea as well as 
in western countries.1,2
Teicoplanin is known to have bi- to tri-exponential distribution features and a Teicoplanin for S. aureus in Neutropenic Fever
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MATERIALS AND METHODS
Teicoplanin susceptibility test of S. aureus 
A total of 78 non-duplicate clinical isolates of S. aureus from 
patients with neutropenic fever at the Catholic Hematopoi-
etic Stem Cell Transplantation (HSCT) Center were col-
lected between 2005 and 2007 for this study. Most of these 
isolates were recovered from blood, wound, or purulent 
discharge. Specimens with possible contaminants or coloni-
zation were all excluded. Cation-adjusted Mueller-Hinton 
agar (Difco laboratories, Detroit, MI, USA) was used for 
tests of teicoplanin susceptibility. The method used for agar 
dilution was based on the protocol published by the Clini-
cal Laboratory Standards Institute for the MIC.11 The inoc-
ulation concentration was -5×105 CFU/mL and the standard 
strain used for quality control was S. aureus ATCC 29213. 
The MICs at which 50% and 90% of the clinical isolates 
were inhibited were defined as MIC50 and MIC90, respec-
tively. A frequency distribution profile was used as PD data 
for the clinical trial simulation. This study was approved by 
the Institutional Review Board of Yeouido St. Mary's Hos-
pital, College of Medicine, The Catholic University of Ko-
rea (Protocol No. GAEUISUNG-1961, Jul/14/2003).
 
Population PK model and simulation 
Population PK parameters of teicoplanin were adopted 
from a published study on neutropenic patients with hema-
tological malignancies because the pharmacokinetic data of 
teicoplanin from Korean patients were not available.12 From 
V1 (central volume of distribution), V2 (peripheral volume 
of distribution), Q (distribution clearance), and CL (elimi-
nation clearance) values and their distribution, 1,000 con-
centration-time profiles for 14 days were generated accord-
ing to several dose regimens using NONMEM (Version 
6.1, Icon Development Solutions, Ellicott City, MD, USA). 
The dose regimens to be considered for clinical application 
were as follows:
1) 400 mg single dose then, 200 mg once a day, by intra-
venous injection (iv)
2) 400 mg every 12 hr for 3 doses then, 400 mg once a 
day, iv (standard regimen)
3) 600 mg every 12 hr for 3 doses then, 400 mg once a 
day, iv
4) 800 mg every 12 hr for 3 doses then, 400 mg once a 
day, iv
5) 400 mg every 12 hr for 3 doses then, 400 mg twice a 
longer elimination half-life than vancomycin, which makes 
its once daily administration possible. It is also generally ac-
cepted that teicoplanin with a trough concentration (Ctrough) 
>10 mg/L is clinically effective; to ensure this trough con-
centration, a dose regimen of 6 mg/kg (400 mg) every 12 
hours for 3 doses, then daily, are the minimal requirements 
for all patients with normal renal function, and a Ctrough of 
20 mg/L should be exceeded in cases of deep-seated staphy-
lococcal infections.3,4 Moreover, according to Harding, et al.,5 
the mean trough concentration was correlated with the clini-
cal outcome of patients with Staphylococcus aureus septice-
mia. MacGowan, et al.6 also demonstrated that the Ctrough 
>10 mg/L and Ctrough >20 mg/L of teicoplanin were related 
to favorable outcomes and curing of staphylococcal infec-
tions, respectively.
Dose regimens based upon trough concentrations have 
not considered the microorganism-specific factors. For the 
appropriate use of an antimicrobial agent, physicians 
should be aware of microorganism-specific as well as pa-
tient-specific factors. To do this, a clear relationship be-
tween pharmacokinetic (PK) and pharmacodynamic (PD) 
interaction of antimicrobial agents must be elucidated. The 
minimum inhibitory concentration (MIC) is one of the mi-
croorganism related factors that requires consideration 
when determining treatment doses and durations for the 
best clinical outcome.7 In the case of glycopeptides, the 
AUC24 (area under the drug concentration-time curve dur-
ing 24 hr) over the MIC i.e., AUC24/MIC that associates 
drug exposure with the characteristics of the microorgan-
ism has recently come into use as a surrogate marker of 
clinical efficacy. However, there has been some debate as to 
the optimal level of this target for treatment using teico-
planin. Although the AUC24/MIC >125 has been regarded 
as a PK-PD marker that can predict clinical success with 
vancomycin treatment,7,8 a level of AUC24/MIC >345 have 
recently been recommended as the target to be attained.9,10 
However, the AUC24/MIC target values for teicoplanin 
treatment have not been extensively studied. Therefore, cli-
nicians have adopted those from vancomycin with the ra-
tionale that both antibiotics belong to the same glycopep-
tide class.
In this context, the present study was performed to assess 
the target attainment rate (TAR) for microorganism-non-
specific (Ctrough) and microorganism-specific (AUC24/MIC) 
targets during two weeks of teicoplanin administration for 
the treatment of S. aureus strains in Korean patients with 
neutropenic fever under several dose regimens. Byung-Jin Ahn, et al.
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variable because the outcome was a categorical variable. 
The logit (P=proportion of target attainment failure at day 
7) meant the log (odds of target attainment failure) and the 
odds of target attainment failure was defined as P/(1-P). A lo-
gistic regression analysis was then performed using NON-
MEM and the logit (P) was back-transformed with the ex-
ponential and P (proportion of target attainment failure) for 
each dose was calculated as follows;
P =
    EXP (logit (P))
      1+EXP (logit (P))
With this information the dose - response (TAR) relation-
ships could be predicted. Fig. 1 summarizes the main steps 
taken in the present study to elucidate the dose-response rela-
tionships of teicoplanin against Staphylococcus aureus in Ko-
rean patients with neutropenic fever.
RESULTS
MIC frequency distribution
The MIC50 and MIC90 of teicoplanin for the S. aureus clini-
cal isolates were 2 and 8 mg/L, respectively. Fig. 2 illus-
trates the frequency distribution of teicoplanin MICs for 78 
clinical isolates of S. aureus. 
   
Target attainment rate under several dosing scenarios
The standard dosing regimen (400 mg every 12 hr for 3 
doses, then 400 mg once a day, iv) recommended by the 
summary in the package insert of teicoplanin for severe in-
fections has a TAR of about 70% under steady-state (SS) 
conditions when Ctrough >10 mg/L and AUC24/MIC >125 
were used as the therapeutic targets of teicoplanin. Howev-
day, iv
After 1,000 virtual concentrations were obtained, for 
each dose scheme, the areas under the curve (AUC) were 
calculated from day 1 to day 14 using non-compartmental 
analysis with the linear trapezoidal method. Covariate ef-
fects were not considered.
Simulation of MIC distribution 
Because we could not define appropriate distribution mod-
els for the histogram of MICs for S. aureus isolated from a 
single HSCT center, simple discrete proportions, as ob-
served in the MIC test histograms, were used instead of as-
suming any distribution model for simulation of 1,000 vir-
tual MICs. Thereafter, these 1,000 simulated MICs were 
randomly allocated to the above 1,000 simulated patients.
Pharmacodynamic assessment 
In each of the 1,000 virtual patients, attainment of microor-
ganism-specific and nonspecific targets (AUC24/MIC >125 
[or 345], Ctrough >10 [or 20] mg/L) were determined for each 
dosing regimen. Thereafter, we calculated the TAR (propor-
tions of patients showing target attainment among 1,000 vir-
tual patients) during two week dosing periods. The AUC24/
MIC >345 and AUC24/MIC >125 among the above targets 
were chosen to determine the relationship of the maintenance 
dose with a steady-state TAR, after seven days of teicoplanin 
administration because these targets were thought to be the 
surrogate marker for clinical outcomes considered with mi-
croorganism specific factors. While the AUC24/MIC >345 
[or 125] was used as a target value, the logit (P=proportion of 
target attainment failure at day 7) was set as an outcome vari-
able and the log (maintenance dose) values as a predictor 
Fig. 1. Summarized study flow to determine the dose-response relationship of teicoplanin against S. aureus in febrile neutropenic Korean 
patients. PK, pharmacokinetic; AUC, area under the curve; MIC, minimum inhibitory concentration.
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log (odds of target attainment failure) and the odds of target 
attainment failure was defined as P/(1-P), logit AUC24/MIC 
<345 or 125) equaled zero at the ED50 and ED50 for each tar-
get  was thereafter calculated as follows:
0=14.6-2.3×log (ED50) (for the AUC24/MIC >345 target)
0=7.8-1.46×log (ED50) (for the AUC24/MIC >125 target)
When the overall clinical success was arbitrarily defined as 
when 80% of the patients with S. aureus infections causing 
er, with an AUC24/MIC >345, only 33% of all patients with 
staphylococcal infection attained the target. When Ctrough 
>20 mg/L was used as a MIC-nonspecific target, less than 
20% of all patients with the adopted PK parameter distribu-
tions achieved the target under SS conditions. Even though 
a 400 mg twice daily dose was given for maintenance, only 
65% achieved a SS-TAR. Table 1 and Fig. 3 show the TARs 
according to several therapeutic targets with several differ-
ent dosing schemes over two weeks of teicoplanin adminis-
tration.
Dose-response relationships
According to several dosing scenarios the logistic regres-
sion models were analyzed with the following equation: 
Logit (AUC24/MIC <345)=14.6-2.3×log (maintenance 
dose)
Logit (AUC24/MIC <125)=7.8-1.46×log (maintenance 
dose)
The dose-response (TAR) relationships observed are 
shown in Fig. 4. For each dosing regimen, the ED50, defined 
as a maintenance dose where 50% of TAR was achieved, 
was around 200 and 600 mg/day in the AUC24/MIC >125 
and AUC24/MIC >345 targets, respectively. Since the logit 
(P=proportion of target attainment failure at day 7) meant the 
Table 1. Rates of Therapeutic Target Attainment Under Several Dosing Scenario in a Population Having High MIC Values for 
Teicoplanin
Dosing regimen Therapeutic target
Teicoplanin administration period
D1 D2 D3 D4 D5 D6 D7 D8 D9 D10 D11 D12 D13 D14
400 mg single dose 
then 200 mg q 24 hr
Ctrough >10 mg/L   0.3   1.9   3.7   6.6   8.7 10.6 12.4 14.9 16.7 17.5 18.4 19.8 20.1 20
Ctrough >20 mg/L 0 0 0 0 0   0.1   0.1   0.2   0.3   0.4   0.5   0.7   0.7 1
AUC24/MIC >125 42.3 37.5 40.9 43 45.2 46.7 48 49.3 49 49.4 49.9 50.3 50.1 49.7
AUC24/MIC >345   1.5   0.8   1.3   2.2   3.2   4.3   4.7   5.1   5.5 6   6.1   6.1   6.5   6.6
400 mg q 12 hr for 3 doses
then 400 mg q 24 hr
Ctrough >10 mg/L 36.2 47 55.4 60.2 64.2 65.3 66.1 67.3 68.4 68.9 69.5 70 70.5 70.4
Ctrough >20 mg/L   1.4   2.7   4.7   7.1  9 11.5 12.6 15.4 17 17.6 18.6 19.8 20.1 20.2
AUC24/MIC >125 72.4 68.4 69.7 70.9 71 71.4 71.8 72.1 72.2 72.4 72.4 72.6 72.9 72.7
AUC24/MIC >345 29.7 23.8 27 29 30.6 31.9 32.7 33.8 34.2 34.9 34.7 35.3 35.6 36.4
600 mg q 12 hr for 3 doses
then 400 mg q 24 hr
Ctrough >10 mg/L 73.7 79.5 75.2 72.7 71.3 70.5 69.9 69.5 69.9 70 70.6 70.8 71.1 70.7
Ctrough >20 mg/L 14.3 20.4 17.5 16.9 16.4 18.7 18.3 19.4 20.3 20.5 20.4 21.4 21.5 21.4
AUC24/MIC >125 78.8 77.5 74.7 73.6 73 72.5 72.5 72.7 72.8 73 72.8 72.7 72.9 72.7
AUC24/MIC >345 45.4 42.2 36.2 35.4 35.3 35.5 35.6 35.8 35.9 36.8 35.9 36.7 36.7 36.9
800 mg q 12 hr for 3 doses
then 400 mg q 24 hr
Ctrough >10 mg/L 90.2 92.8 86.1 80.9 77.4 74.1 72.4 71.9 71.2 71.8 71.1 71.5 71.4 71.1
Ctrough >20 mg/L 36.2 47 36.4 30.6 26.6 25.4 24.1 24.2 23.4 23.5 22.7 22.7 23.1 22.5
AUC24/MIC >125 83.3 82.2 77.3 76 74.7 74 73.4 73.6 73.3 73.2 73 73 73.4 73
AUC24/MIC >345 60.2 56.3 45.2 41.2 39.5 39.1 38.2 38.4 37.8 38.1 37.2 37.7 37.5 37.7
400 mg q 12 hr for 3 doses
then 400 mg q 12 hr
Ctrough >10 mg/L 36.2 80.6 92.4 94.8 96.3 96.7 96.4 96.9 97.1 96.6 96.8 96.7 97 96.5
Ctrough >20 mg/L   1.4 21.1 43.1 58 64.2 67.9 70.5 73.6 74 75.7 75.8 76.3 77.2 76.8
AUC24/MIC >125 72.4 78.3 80.6 82.8 85.3 86.8 87.3 88.4 88.7 89.2 89.2 89.4 89.5 89.9
AUC24/MIC >345 29.7 43.4 52.4 58.8 61 62.4 64 64.7 65.1 65.7 66.1 66.7 66.5 66.7
MIC, minimum inhibitory concentration; AVC, area under the curve.
Fig. 2. Frequency distribution of teicoplanin MIC for 78 S. aureus isolates 
from patients with neutropenic fever patients at the Catholic hematopoietic 
stem cell transplantation center, Seoul, Korea through 2005-2007. MIC, min-
imum inhibitory concentration.
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DISCUSSION
According to a recent meta-analysis of 24 randomized con-
trolled trials that compared vancomycin to teicoplanin, 
there were no significant differences between teicoplanin 
and vancomycin in terms of efficiency outcomes, such as 
clinical and microbiological failure rate; however, teico-
planin was associated with a lower occurrence of adverse 
neutropenia reached the target, the maintenance dose for 
overall clinical success was predicted to be about 540 and 
1,000 mg/day in the AUC24/MIC >125 and AUC24/MIC 
>345 targets, respectively, and the maintenance dose for 
each target was obtained as follows:
Log (0.2/(1-0.2))=14.6-2.3×log (maintenance dose) 
(for the AUC24/MIC >345 target)
Log (0.2/(1-0.2))=7.8-1.46×log (maintenance dose)             
(for the AUC24/MIC >125 target)
Fig. 3. TARs according to several therapeutic targets with several dosing schemes during 2 weeks of teicoplanin administration; TAR for 
Ctrough >10 mg/L, Ctrough >20 mg/L, AUC24/MIC >125 and AUC24/MIC >345. TAR, target attainment rate; AUC, area under the curve; MIC, mini-
mum inhibitory concentration.
Fig. 4. Maintenance dose - response (TAR) relationships obtained from logistic regression; ED50, defined as a maintenance dose where 
50% TAR was achieved; TAR for AUC24/MIC >345 (open circle) or 125 (closed rectangle). TAR, target attainment rate; AUC, area under the 
curve; MIC, minimum inhibitory concentration.
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tribution, as compared to healthy controls. Therefore, in this 
specific population, the trough concentration was associat-
ed with increased clearance and higher initial doses are re-
quired; administration of 6 mg/kg teicoplanin given every 
12 hr for five doses ensured a mean trough serum concen-
tration of 16.0 mg/L, with a trough concentration below 10 
mg/L in 7% of patients, compared with 46% of patients on 
a regimen of teicoplanin given only four times during the 
first 48 h. According to Pea, et al.,19 to ensure early thera-
peutically effective trough concentrations (more than 10 
mg/L at 24 h) in patients with acute leukemia, a high load-
ing regimen (800 mg+400 mg 12 hr apart on day 1,600 mg 
+400 mg 12 hr apart on day 2) followed by a high mainte-
nance regimen (400 mg every 12 hr from day 3 on) showed 
successful attainment of the initial target.
It is known that glycopeptide antibiotics have a time-de-
pendent killing pattern and moderate post-antibiotic effects. 
Thus, the ideal dosing regimen for a glycopeptide should 
be designed to maximize the amount of drug received. The 
AUC24/MIC value could be used as the surrogate parameter 
associated with clinical efficacy. Unfortunately, PD data and 
AUC24/MIC target value are not available for teicoplanin. 
Therefore, the values known for the vancomycin target value 
were adopted. Although past recommendations had indicated 
that at least an AUC24/MIC >125 was necessary for vanco-
mycin, recent studies recommend an AUC24/MIC >345 or 
400.20-23 Rybak, et al.24 recommended that, for complicated 
infections caused by S. aureus, trough vancomycin concen-
trations of 15-20 mg/L should be obtained and the range 
should achieve an AUC/MIC >400 for most patients if the 
MIC is <1 mg/L. However, an AUC/MIC of >400 is not at-
tainable with conventional doses when the MIC is more 
than 2 mg/L in patients with normal renal function. In that 
situation, alternative therapies should be considered. There-
fore, it is predicted that if the present study chose an AUC24/
MIC >400 as an attainable target, the TARs would show 
lower values than noted in the present results and larger tei-
coplanin doses would be needed for a favorable clinical 
outcome in this specific patient population with neutropenic 
fever. However, when the present study results were com-
pared to clinical results from a study conducted at the same 
institution in which the clinical and microbiological response 
in febrile neutropenic patients were 53.3% and 62.5% for 
200 mg/day maintenance dose regimen, the results using 
AUC24/MIC >125 target was more consistent with clinical 
results than those from the AUC24/MIC >345 target.2 Based 
upon this correlation between AUC24/MIC >125 target and 
events than vancomycin.13
Although teicoplanin has been widely used for infections 
associated with hematological malignancies in Korea, due to 
its low rate of adverse drug reactions, a population-specific 
optimum dose regimen has not been established with respect 
to its association with the PK/PD. Therefore, the goal of this 
study was to determine the appropriate teicoplanin-dosing 
strategy for adequate treatment of S. aureus in Korean pa-
tients with neutropenic fever.
To determine the effective dose regimen, validated end-
points or surrogate markers for clinical success or failure are 
required. In the case of teicoplanin, the trough concentration 
and AUC24/MIC are considered as microorganism-nonspecif-
ic and microorganism-specific markers, respectively. More-
over, the time to achieve a target value for the above marker 
must also be considered to associate the above markers with 
the clinical outcome. Because the loading dose could be 
readily determined from the maintenance dose using PK 
principles, for simplicity, the TAR with regard to the mainte-
nance dose was studied. Both the trough concentration and 
AUC24/MIC are associated with the PK properties of a spe-
cific population, i.e., patients with neutropenic fever that 
have hematological malignancies. While the trough concen-
tration is directly related to the dose regimen and the patient 
pharmacokinetics, for the AUC24/MIC, the MIC value for 
the microorganism has to be considered as well.
In a study reported by Whitehouse, et al.14 on teicoplanin 
PK in critically ill patients with renal impairment, the trough 
concentrations were not significantly different in the pa-
tients that were cured (mean 5.2-8.7 mg/L) and in those that   
failed to respond to treatment (mean 9.3-12.1 mg/L). Ac-
cording to Gimenez, et al.,15 eight out of 10 patients had 
trough concentration values below 10 mg/L at 48 hrs after a 
standard regimen treatment of patients with neutropenia 
due to underlying hematological disease. The initial inade-
quate concentrations during the first few days of therapy 
may affect the outcome of teicoplanin therapy with regard 
to the emergence of resistant microorganisms, and thus sub-
therapeutic concentrations should be avoided.16 Especially 
in the critically ill patient setting, loading doses of teico-
planin (6 mg/kg every 12 hrs for at least three doses) should 
be considered mandatory in all patients and individually 
optimized dose regimens optimized. In addition, drug level 
monitoring is important during treatment.17
Lothorary, et al.12,18 reported that patients with neutrope-
nic fever have an increased distribution and elimination 
clearance without significant changes in the volume of dis-Byung-Jin Ahn, et al.
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limitations of the present study were that PK parameters 
from the literature were adopted instead of being based on 
the values of the patients in the study and the MIC values 
from single hospital in Korea were used. Therefore, addi-
tional well-designed prospective PK/PD outcome studies 
are needed to guide the optimal dosing regimens for specif-
ic patient populations.
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